Barclays’s Aerie Pharmaceuticals AERI Stock Holding History

Barclays’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-51,000	Closed	-$1.84M	–	7452
2018 Q4	$1.84M	Sell	51,000 -10,000	-16%	-$469K	﹤0.01%	2487
2018 Q3	$3.75M	Buy	+61,000	New	+$3.92M	﹤0.01%	2124
2017 Q2	–	Sell	-20,600	Closed	-$934K	–	7044
2017 Q1	$934K	Buy	+20,600	New	+$919K	﹤0.01%	2800
2016 Q4	–	Sell	-91,800	Closed	-$3.46M	–	6916
2016 Q3	$3.46M	Buy	+91,800	New	+$2.02M	﹤0.01%	1563
2015 Q2	–	Sell	-4,100	Closed	-$127K	–	7278
2015 Q1	$127K	Buy	+4,100	New	+$119K	﹤0.01%	4688

Barclays's AERI Position: Q4 2022 in Review

Barclays sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 30,316 shares — an estimated $459K sold.

Barclays first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $9.25M in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Barclays reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Barclays sold 30,316 Aerie Pharmaceuticals shares in Q4 2022, an estimated $459K.
Barclays first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
Barclays's Aerie Pharmaceuticals position peaked at $9.25M in Q3 2016.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.